Comparing IVF/ICSI Cycle Outcomes of Post Ovulation Ovarian Stimulation Protocol with Elonva Without GnRH Antagonist to Follicular Phase Day 2 Stimulation Fixed Day 5 Antagonist Protocol

Launched by ART FERTILITY CLINICS LLC · Mar 11, 2025

Keywords

ClinConnect Summary

This clinical trial is studying two different methods of ovarian stimulation during in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) cycles. The main goal is to see if a new approach, which uses a medication called Elonva without a specific hormone blocker (GnRH antagonist), can be as effective as the traditional method that uses a hormone blocker on a fixed schedule. The researchers believe that after ovulation, the body naturally produces enough progesterone to prevent premature ovulation, which could help reduce treatment costs and simplify the IVF process without affecting the chances of success.

To participate in this trial, women aged 18 to 38, with regular menstrual cycles and certain hormone levels, may be eligible. However, those with specific conditions like premature ovulation, polycystic ovary syndrome (PCOS), or endometriosis cannot join. If you are selected to participate, you can expect to undergo one of the two ovarian stimulation methods being tested. This trial is still in the planning stages and hasn't started recruiting participants yet, so there will be more information available as it progresses.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Age 18 to 38 years old.
• • Normal Menstrual cycle of 25-35 days.
• • Body Weight 60to90 kg
• • AMH\>1.3 - \<3 ng/m (Ferraretti and Gianaroli, 2014; Calzada et al., 2019) an antral follicle count (AFC) of \>5 on menstrual cycle days 2-3,
• Exclusion Criteria:
• • History of premature ovulation
• • Azoospermia
• • PCOS
• • Endometriosis AFS ¾
• • Endometrioma
• • Known chromosomal abnormalities